Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buccalin in the prophylaxis of recurrent lower respiratory tract infections
NCT06736288Phase 4
Key facts
- Status
- Recruiting
- Start
- Oct 2025
- Primary completion
- Apr 2027
- Countries
- 2
- Sponsor
- Laboratorio Farmaceutico SIT
- Modality
- Vaccines & Immunotherapeutics
- Drugs
- Buccalin
- Conditions
- lower respiratory tract infection (LRTI)
01
Overview
Phase 4, randomised, double-blind trial in lower respiratory tract infection (LRTI) comparing Buccalin with Placebo (2 arms). Primary endpoint: Reduction in the number of infection episodes at 12 months. Started Oct 2025; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Buccalin
Active treatment with bacterial lysate tablets.
Placebo
Placebo comparator.
03
Who it enrols
Adults with recurrent lower respiratory tract infections (>=2 episodes in previous 12 months and >=2 during run-in) excluding those with pneumonia, TB, cystic fibrosis, or immunodeficiency.
04
Endpoints
Primary
Reduction in the number of infection episodes
Secondary
Safety of Buccalin
Beyond the preview
Go deeper on NCT06736288.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06736288.